GlassScriptPrepare for your visit
James X Xu
Hematology & Oncology · Rockville, MD · NPI 1104003342
One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.
What was reported
$9,576.16
in general payments reported to CMS, 2019-2025 · $2,499 in 2025
The $2,499 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Who reported paying
General payments only, top 6 by amount.
- Novartis Pharmaceuticals Corporation $1,168.17
- Janssen Biotech, INC. $638.59
- Pfizer INC. $558.33
- Astrazeneca Pharmaceuticals LP $481.00
- Boston Scientific Corporation $385.21
- Merck Sharp & Dohme LLC $343.39
Drugs and devices associated with these payments
Keytruda Pluvicto Imfinzi Imbruvica Opdivo Xtandi Erleada Kisqali Scemblix Udenyca Braftovi Lutathera
Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.
Questions you might ask
- I saw James Xu listed in the CMS Open Payments database. Can you tell me about your work with those companies?
- Is there a generic or alternative to this medication, and would it work as well for me?
- What made you choose this particular treatment for my situation?
These are normal questions. A good clinician will welcome them.
Notes
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.
GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/1248414/james-x-xu